GPCR — Structure Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1888886 ·
Last close
$18.17
Market Cap
$1.30B
52W High
$94.90
52W Low
$17.81
ADV30
1,051,534
Next earnings
—
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -156,333,000 -144,757,000 1,334,419,000 222,033,000 112,549,000
Jun 2026 0 — -118,630,000 -106,159,000 1,425,415,000 272,638,000 71,011,000
Mar 2026 0 — -89,379,000 -75,968,000 1,508,124,000 316,168,000 61,030,000
Dec 2025 0 — 13,740,000 33,004,000 1,583,918,000 799,623,000 67,541,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-270,997,000
Investing CF
$-315,946,000
Financing CF
$706,064,000
CapEx
$-7,895,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.03
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-797,184,000
Inventory
—
Receivables
$0
ST Investments
$1,017,942,000
EBIT TTM
$-350,602,000
Pretax Income TTM
$-293,115,000
Interest Exp TTM
—
Analysts
14

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -186,809,000 -141,202,000 1,583,918,000 67,541,000 1,516,377,000 -222,199,000
Dec 2024 0 -158,228,000 -122,526,000 903,330,000 38,487,000 864,843,000 -116,636,000
Dec 2023 0 -102,775,000 -89,620,000 482,017,000 29,051,000 452,966,000 -79,488,000
Dec 2022 0 -52,561,000 -51,321,000 97,845,000 212,985,000 -115,140,000 -46,120,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-214,835,000
OpCashFlow TTM
—
Assets (Latest)
$1,425,415,000
Forward EPS
$-2.50

Peers — same industry

TickerNameMarket CapLastDaily %
INVA Innoviva, Inc. $1.30B $18.30 —
LBRX LB PHARMACEUTICALS INC $1.30B $40.30 —
MNKD MANNKIND CORP $1.31B $4.07 —
MLYS Mineralys Therapeutics, Inc. $1.28B $14.48 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —

News headlines (Yahoo Finance, 1h cache)

Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
2026-11-16 23:20 · Yahoo
Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
2026-11-12 12:00 · Yahoo
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-09 21:05 · Yahoo
Raised Guidance Could Change The Case For Schrödinger Stock (SDGR)
2026-11-07 20:12 · Yahoo
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-11-04 12:30 · Yahoo
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
2026-10-19 20:13 · Yahoo
Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
2026-10-17 03:23 · Yahoo
What Schrodinger (SDGR) Said on Its Q3 Earnings Call
2026-11-05 04:14 · Yahoo
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
2026-11-13 13:13 · Yahoo
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
2026-11-11 15:56 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.